Search Science Hub

Science Hub is Novo Nordisk’s one-stop portal for all our scientific publications and clinical trials, congress materials and medical updates. Sign up to gain full access.

Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

ADA 2026 5 - 8 June 2026

Greater combined A1C reductions and weight loss with 25 mg and 50 mg versus 14 mg oral semaglutide in adults with T2D: evidence from PIONEER PLUS

Authors :

Jens Aberle¹; Pawel Bogdanski²; Erik Ising³; Chethana KR⁴; Anusha Jahagirdar⁴; Sue D. Pedersen⁵

Affiliations

View Details Hide Details

Download .PDF

Keywords

Diabetes

Congress poster

GLP-1 RA

Semaglutide (oral)

PHASE 3 (RCT)